Drugs / hyaluronic acid-carboxymethylcellulose
hyaluronic acid-carboxymethylcellulose
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT02773251 | Nov 2011 → Jun 2014 | prostate cancer | Bucheon St. Mary's Hospital | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | hyaluronic acid-carboxymethylcellulose | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02773251 ↗ |
| Known as | Guardix-sol | “using HA/CMC (marketed as Guardix-sol®, Hanmi Medicare, Seoul, Korea)” NCT02773251 ↗ |
| Known as | HA/CMC | “using HA/CMC (marketed as Guardix-sol®, Hanmi Medicare, Seoul, Korea)” NCT02773251 ↗ |